

GERM™



ETFMG Treatments, Testing and Advancements ETF

as of 6/17/20

GERM is designed to give direct exposure to the biotech companies engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies.



From Jan. 2011 to Jan. 2018 there were 36 epidemic events in the U.S. alone.¹



There are 20 combined pandemics and epidemics affecting the world today.³



New reports indicate the value of the global human vaccines market is expected to grow to \$72.5 billion by 2024, representing a CAGR of 11.2% from 2016 to 2024.²



Variations of Coronavirus have been medically documented in approx. 9 instances since 1965.⁴


Performance

	CUMULATIVE				ANNUALIZED				
	1 MONTH	3 MONTH	YTD	SINCE INCEP.	1 YEAR	3 YEARS	5 YEARS	10 YEARS	SINCE INCEP.
MARKET PRICE									
NAV									
INDEX									

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the Funds may be lower or higher than the performance quoted. All performance is historical and includes reinvestment of dividends and capital gains. Performance data current to the most recent month end may be obtained by calling 1-844-ETF-MGRS (1-844-383-6477). Performance is annualized for periods greater than 1 year.

Prime Classification Weighting Distribution

As of 6/7/20



Did You Know?

The frequency and diversity of disease outbreaks have grown steadily for the past 30 years. Growth in travel, trade and connectivity are key factors.⁵

The global* vaccines market is one of the fastest growing biotech segments.²

FOR MORE INFORMATION

Website: etfmg.com/GERM
 Email: info@etfmg.com
 Sales Inquiries: 1.844.ETF.MGRS

FUND INFORMATION

Fund Inception: 6/17/20
 Ticker: GERM
 CUSIP: 26924G763
 ISIN: US26924G7631
 Stock Exchange: NYSE ARCA
 Expense Ratio: 0.68%
 Security Lending Income⁶: --
 Intraday NAV (IIV): --
 NAV Symbol: GERM.NV
 Rebalance Freq.: Quarterly

TOP 10 FUND HOLDINGS (%)

Alnylam Pharmaceuticals Inc 6.00
 Bio Rad Laboratories Inc 6.00
 Lab Corp of America Holdings 6.00
 Moderna Inc 6.00
 Quest Diagnostics Inc 6.00
 Adaptive Biotechnologies Corp 4.00
 BioNTech SE 4.00
 Emergent BioSolutions Inc 4.00
 Novavax Inc 4.00
 Quidel Corp 4.00

KEY INDEX FACTS

Index Provider: Prime Indexes
 No. of Holdings⁷: 56
 Index Ticker: PGERM

etfmg.com/GERM

This fund is a series in the ETF Managers Trust

*GERM invests in U.S.-listed holdings that are active in the global biotech industry.

About the Fund

The ETFMG Treatments, Testing and Advancements ETF (GERM) holds U.S.-listed companies engaged in and at the forefront of R&D, vaccines, therapies and testing technologies.

The Fund's investment objective seeks to provide investment results that, before fees and expenses correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index.

About the Index

The Prime Treatments, Testing and Advancements Index (the "Index") is an Index of Prime Indexes, a division of Level ETF Ventures LLC. The Index has been created to provide investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.

The Index is designed to include the securities of companies engaged in performing research, development and commercialization of treatments, vaccines or biological testing for infectious diseases. These companies are known collectively as "Treatments, Testing and Advancement Companies."

Carefully consider the Fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Fund's prospectus, which may be obtained by calling 1-844-ETF-MGRS (1-844-383-6477), or by visiting www.etfmg.com/GERM. Read the prospectus carefully before investing.

¹ World Health Organization, "Managing Epidemics", page 22: <https://www.who.int/emergencies/diseases/managing-epidemics-interactive.pdf?ua=1>

² Vaccines and Vaccination conference series, Transparency Market Research, June 2020, Market analysis: <https://europe.vaccineconferences.com>

³ World Health Organization: <https://www.who.int/emergencies/diseases/en/>

⁴ "The Scientist": A Brief History of Human Coronavirus 6/2/2020: <https://www.the-scientist.com/news-opinion/a-brief-history-of-human-coronaviruses-67600>

⁵ World Economic Forum white paper, "Outbreak Readiness and Business Impact Protecting Lives and Livelihoods across the Global Economy", in collaboration with Harvard Global Health Institute, Jan. 2019 http://www3.weforum.org/docs/WEF%20HGH_I_Outbreak_Readiness_Business_Impact.pdf

⁶ Security Lending Income is expressed as the result of dividing net securities lending income for the twelve months ending 12/31/20 divided by the average daily net assets of the Fund for the same period.

⁷ Holdings are subject to change.

Investing involves risk, including loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Narrowly focused investments typically exhibit higher volatility. Treatment Companies and Testing Companies are involved in discovering, developing and commercializing novel drugs or tests with significant market potential. These companies face challenges including pre-clinical testing and clinical trial stages of development. Clinical trials may be delayed and certain programs may never advance in the clinic or may be more costly to conduct than anticipated. Such companies may be dependent on their ability to secure significant funding for research, development, and commercialization of therapeutics, vaccines, tests, and other health care products or services. If there are delays in obtaining required regulatory and marketing approvals for products, the ability of such companies to generate revenue may be materially impaired. If regulatory approval is obtained, products will still remain subject to regulatory scrutiny with regulatory authorities having the ability to impose significant restrictions on the indicated uses or marketing. Lastly, even if a licensed product is achieved, such companies may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping.

The Fund is a recently organized, non-diversified management investment company with limited operating history.

ETF Managers Group LLC is the investment adviser to the Fund.

The Fund is distributed by ETFMG Financial LLC. ETF Managers Group LLC and ETFMG Financial LLC are wholly owned subsidiaries of Exchange Traded Managers Group LLC (collectively, "ETFMG"). ETFMG Financial LLC is not affiliated with Prime Indexes.